Cargando…

Extremes of both weight gain and weight loss are associated with increased incidence of heart failure and cardiovascular death: evidence from the CANVAS Program and CREDENCE

BACKGROUND: Obesity is an independent risk factor for cardiovascular disease (CVD) in patients with type 2 diabetes (T2D). However, it is not known to what extent weight fluctuations might be associated with adverse outcomes. We aimed at assessing the associations between extreme weight changes and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrannini, Giulia, Pollock, Carol, Natali, Andrea, Yavin, Yshai, Mahaffey, Kenneth W., Ferrannini, Ele
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10149021/ https://www.ncbi.nlm.nih.gov/pubmed/37120538 http://dx.doi.org/10.1186/s12933-023-01832-5

Ejemplares similares

Liver function markers predict cardiovascular and renal outcomes in the CANVAS Program
por: Ferrannini, Giulia, et al.
Publicado: (2022)

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials
por: Fletcher, Robert A., et al.
Publicado: (2023)

Insulin growth factor axis and cardio-renal risk in diabetic kidney disease: an analysis from the CREDENCE trial
por: Mohebi, Reza, et al.
Publicado: (2023)

Body Weight, Not Insulin Sensitivity or Secretion, May Predict Spontaneous Weight Changes in Nondiabetic and Prediabetic Subjects: The RISC Study
por: Rebelos, Eleni, et al.
Publicado: (2011)

Effects of the SGLT2 inhibitor canagliflozin on plasma biomarkers TNFR-1, TNFR-2 and KIM-1 in the CANVAS trial
por: Sen, Taha, et al.
Publicado: (2021)

Effects of GLP-1 receptor agonists and SGLT-2 inhibitors on cardiac structure and function: a narrative review of clinical evidence
por: Natali, Andrea, et al.
Publicado: (2021)

Response to Comment on: Ferrannini. Learning From Glycosuria. Diabetes 2011;60:695–696
por: Ferrannini, Ele
Publicado: (2011)

Learning From Glycosuria
por: Ferrannini, Ele
Publicado: (2011)

A Journey in Diabetes: From Clinical Physiology to Novel Therapeutics: The 2020 Banting Medal for Scientific Achievement Lecture
por: Ferrannini, Ele
Publicado: (2021)

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
por: Mahaffey, Kenneth W., et al.
Publicado: (2019)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Optimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
por: Neal, Bruce, et al.
Publicado: (2017)

Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition
por: Ferrannini, Giulia, et al.
Publicado: (2015)

Impact of Different Bariatric Surgical Procedures on Insulin Action and β-Cell Function in Type 2 Diabetes
por: Ferrannini, Ele, et al.
Publicado: (2009)

Anti-inflammatory properties of antidiabetic drugs: A “promised land” in the COVID-19 era?
por: Katsiki, Niki, et al.
Publicado: (2020)

Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye?
por: Ferrannini, Ele, et al.
Publicado: (2021)

Role of anatomical location, cellular phenotype and perfusion of adipose tissue in intermediary metabolism: A narrative review
por: Camastra, Stefania, et al.
Publicado: (2022)

Erratum. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
por: Ferrannini, Ele, et al.
Publicado: (2021)

Canagliflozin, a sodium glucose co-transporter 2 inhibitor, improves model-based indices of beta cell function in patients with type 2 diabetes
por: Polidori, David, et al.
Publicado: (2014)

Plasma mannose as a novel marker of myocardial infarction across different glycaemic states: a case control study
por: Fortin, Elena, et al.
Publicado: (2022)

Redefining the Diagnosis of Diabetes Using Glycated Hemoglobin
por: Fonseca, Vivian, et al.
Publicado: (2009)

Canva
por: Gehred, Alison Paige
Publicado: (2020)

Of credence and credibility: A year gone by
por: Jain, Sanjay N
Publicado: (2014)

Commentary: Religious credence is not factual belief
por: Talmont-Kaminski, Konrad
Publicado: (2016)

Effects of canagliflozin on initiation of insulin and other antihyperglycaemic agents in the CANVAS Program
por: Matthews, David R., et al.
Publicado: (2020)

Empagliflozin improves insulin sensitivity in patients with recent acute coronary syndrome and newly detected dysglycaemia: Experiences from the randomized, controlled SOCOGAMI trial
por: Fortin, Elena, et al.
Publicado: (2023)

Influence of Hyperinsulinemia and Insulin Resistance on In Vivo β-Cell Function: Their Role in Human β-Cell Dysfunction
por: Mari, Andrea, et al.
Publicado: (2011)

Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study
por: Baldi, Simona, et al.
Publicado: (2013)

Anti-inflammatory and Antioxidant Properties of HDLs Are Impaired in Type 2 Diabetes
por: Morgantini, Cecilia, et al.
Publicado: (2011)

Differential Proteomics of Cardiovascular Risk and Coronary Artery Disease in Humans
por: Ferrannini, Ele, et al.
Publicado: (2022)

Risk Factors for Fracture in Patients with Coexisting Chronic Kidney Disease and Type 2 Diabetes: An Observational Analysis from the CREDENCE Trial
por: Young, Tamara K., et al.
Publicado: (2022)

Renal Glucose Handling: Impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2013)

Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves ß‐cell function in people with type 2 diabetes
por: Ferrannini, Ele, et al.
Publicado: (2022)

Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes
por: Haukka, Jani K., et al.
Publicado: (2018)

HTML5 canvas
por: Fulton, Steve, et al.
Publicado: (2013)

HTML5 Canvas
por: Fulton, Steve, et al.
Publicado: (2011)

CANVAS is an Oligosymptomatic Disease
por: Ruiz-Fernández, Emilio, et al.
Publicado: (2022)

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial
por: Li, Jing‐Wei, et al.
Publicado: (2022)

Progression to Diabetes in Relatives of Type 1 Diabetic Patients: Mechanisms and Mode of Onset
por: Ferrannini, Ele, et al.
Publicado: (2010)

Human Insulin Resistance Is Associated With Increased Plasma Levels of 12α-Hydroxylated Bile Acids
por: Haeusler, Rebecca A., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_qtj6ci6c0o05thrg5nr65ecd6k